M Rauvala1, U Puistola, T Turpeenniemi-Hujanen. 1. Department of Obstetrics and Gynecology, The University Hospital of Oulu, PL 24, Fin-90029 OYS, Oulu, Finland. marita.rauvala@oulu.fi
Abstract
OBJECTIVE: In the present study, the significance of circulating matrix metalloproteinases -2 and -9 (MMP-2, MMP-9), as well as their tissue inhibitors -1 and -2 (TIMP-1, TIMP-2) in ovarian cancer were studied to assess the possibility of using them in clinical decision-making. METHODS: We measured, prior to primary surgery, the concentrations of these proteins in serum samples of 115 patients with an ovarian tumor: 63 with cancer, 6 with a low malignant potential tumor, and 46 with a benign tumor. The measurements were performed with enzyme-linked immunosorbent assays (ELISA). The results were compared to clinicopathological data. RESULTS: A high serum concentration of TIMP-1 at diagnosis was found to correlate with the malignant phenotype of an ovarian tumor. Within malignant neoplasias, high circulating TIMP-1 correlated to the aggressive phenotype and unfavorable prognosis. An association was found between a high serum level of TIMP-1 and an advanced stage of the disease, a residual tumor>2 cm, poor response to cytotoxic treatment, shorter recurrence free time, and shorter cancer-related overall survival. No statistically significant correlation was found between the circulating gelatinases (MMP-2, MMP-9) or TIMP-2 and the clinicopathological factors. However, a tendency for better survival with high serum concentration of TIMP-2 or MMP-2 was observed. CONCLUSION: We conclude that an elevated preoperative serum TIMP-1 concentration correlates to the aggressive behavior of ovarian cancer.
OBJECTIVE: In the present study, the significance of circulating matrix metalloproteinases -2 and -9 (MMP-2, MMP-9), as well as their tissue inhibitors -1 and -2 (TIMP-1, TIMP-2) in ovarian cancer were studied to assess the possibility of using them in clinical decision-making. METHODS: We measured, prior to primary surgery, the concentrations of these proteins in serum samples of 115 patients with an ovarian tumor: 63 with cancer, 6 with a low malignant potential tumor, and 46 with a benign tumor. The measurements were performed with enzyme-linked immunosorbent assays (ELISA). The results were compared to clinicopathological data. RESULTS: A high serum concentration of TIMP-1 at diagnosis was found to correlate with the malignant phenotype of an ovarian tumor. Within malignant neoplasias, high circulating TIMP-1 correlated to the aggressive phenotype and unfavorable prognosis. An association was found between a high serum level of TIMP-1 and an advanced stage of the disease, a residual tumor>2 cm, poor response to cytotoxic treatment, shorter recurrence free time, and shorter cancer-related overall survival. No statistically significant correlation was found between the circulating gelatinases (MMP-2, MMP-9) or TIMP-2 and the clinicopathological factors. However, a tendency for better survival with high serum concentration of TIMP-2 or MMP-2 was observed. CONCLUSION: We conclude that an elevated preoperative serum TIMP-1 concentration correlates to the aggressive behavior of ovarian cancer.
Authors: H Cui; B Seubert; E Stahl; H Dietz; U Reuning; L Moreno-Leon; M Ilie; P Hofman; H Nagase; B Mari; A Krüger Journal: Oncogene Date: 2014-09-29 Impact factor: 9.867
Authors: Zoya Yurkovetsky; Steven Skates; Aleksey Lomakin; Brian Nolen; Trenton Pulsipher; Francesmary Modugno; Jeffrey Marks; Andrew Godwin; Elieser Gorelik; Ian Jacobs; Usha Menon; Karen Lu; Donna Badgwell; Robert C Bast; Anna E Lokshin Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: Lynn M Amon; Wendy Law; Matthew P Fitzgibbon; Jennifer A Gross; Kathy O'Briant; Amelia Peterson; Charles Drescher; Daniel B Martin; Martin McIntosh Journal: PLoS One Date: 2010-06-15 Impact factor: 3.240
Authors: Sven Mahner; Linn Woelber; Christine Eulenburg; Joerg Schwarz; Walter Carney; Fritz Jaenicke; Karin Milde-Langosch; Volkmar Mueller Journal: BMC Cancer Date: 2010-04-13 Impact factor: 4.430
Authors: Erica L Johnson; Rajesh Singh; Shailesh Singh; Crystal M Johnson-Holiday; William E Grizzle; Edward E Partridge; James W Lillard Journal: World J Surg Oncol Date: 2010-07-22 Impact factor: 2.754